GXMC
TVTX icon

Global X Management Company’s Travere Therapeutics TVTX Stock Holding History

Global X Management Company’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-520
Closed -$17K – 1007
2015
Q2 		$17K Buy
+520
New +$14.2K ﹤0.01% 502
2014
Q3 		– Sell
-1,701
Closed -$20K – 553
2014
Q2 		$20K Buy
+1,701
New +$23K ﹤0.01% 512

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Global X Management Company's TVTX Position: Q3 2015 in Review

Global X Management Company sold out of Travere Therapeutics (TVTX) in Q3 2015, closing a stake of 520 shares — an estimated $17K sold.

Global X Management Company first reported a position in TVTX in Q2 2014 and held it in 2 quarters. The position peaked at $20K in Q2 2014. 133 funds tracked by Wall St. Rank hold TVTX as of Q3 2015.

  • Global X Management Company reported no remaining Travere Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Global X Management Company sold 520 Travere Therapeutics shares in Q3 2015, an estimated $17K.
  • Global X Management Company first reported a position in Travere Therapeutics in Q2 2014 and held it in 2 quarters.
  • Global X Management Company's Travere Therapeutics position peaked at $20K in Q2 2014.
  • 133 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2015.

Based on Global X Management Company's 13F filing for Q3 2015, filed 12 Nov 2015.